LLF580
Total Payments
$257,337
Transactions
3
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $5,360 | 1 | 0 |
| 2019 | $87,780 | 1 | 0 |
| 2018 | $164,197 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $257,337 | 3 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 12 WEEK PHASE IB RANDOMIZED INVESTIGATOR AND SUBJECT BLINDED PLACEBO CONTROLLED REPEAT DOSE STUDY OF LLF580 | Novartis Pharmaceuticals Corporation | $257,337 | 0 |
Top Doctors Receiving Payments for LLF580
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Overland Park, KS | $257,337 | 3 |
Ad
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $257,337
Product Information
- Type Drug
- Total Payments $257,337
- Total Doctors 0
- Transactions 3
About LLF580
LLF580 is a drug associated with $257,337 in payments to 0 healthcare providers, recorded across 3 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2018 to 2020. In 2020, $5,360 was paid across 1 transactions to 0 doctors.
The most common payment nature for LLF580 is "Unspecified" ($257,337, 100.0% of total).
LLF580 is associated with 1 research study, including "A 12 WEEK PHASE IB RANDOMIZED INVESTIGATOR AND SUBJECT BLINDED PLACEBO CONTROLLED REPEAT DOSE STUDY OF LLF580" ($257,337).